Zydus Lifesciences Limited

BSE: ZYDUSLIFE532321ISIN INE010B01027

Healthcare
Pharmaceuticals
BSE 200

BSE listing

Share price

₹1,153.00+15.65 (+1.38%)

as of 18 Sep 2026

52W high: ₹1,205.65
52W low: ₹835.85
Off 52W high: -4.37%
1M return: +4.34%
3M return: +7.67%
6M return: +29.46%
1Y return: +10.03%
20D avg volume: 83,836
50 DMA: ₹1,134.05
200 DMA: ₹1,000.05

Key ratios Consolidated

Market cap: ₹1,15,012 Cr
Current price: ₹1,153.00
52W high / low: ₹1,205.65 / ₹835.85
Face value: ₹1.00
P/E: 25.04
P/B: —
EPS (TTM): ₹46.04
Book value / share: —
ROE: —
ROCE: 19.20%
Operating margin: —
Net margin: —
Debt / equity: 0.40
Net debt: ₹10,914 Cr
Interest cover: 16.09
Dividend yield: 0.09%
Dividend / share (TTM): ₹1.00
Payout: 2.17%
Cash conversion cycle: 110.2 days

About

In plain English

Zydus Lifesciences is a big Indian healthcare company that makes a wide range of products, from prescription drugs and vaccines to consumer wellness brands like SugarFree and Glucon-D, and even medical devices like hip and knee replacements. For example, they sell medicines for cancer and heart disease to hospitals and pharmacies in India, and they are a top-3 seller of generic drugs in the US, which are cheaper copies of brand-name pills. They also make things like the world's first biosimilar of a major cancer drug (Nivolumab) and a new oral medicine for a rare liver disease. Their customers include doctors, patients, government health programs, and consumers who buy their wellness products online or in stores. They make money by selling these products across India, the US, and other countries, with a big focus on innovative, high-margin drugs and devices.

AI-generated summary, written from the company's own filings and disclosures. Every figure elsewhere on this page comes from exchange data, not from a model. See our editorial standards. Generated 23 Aug 2026.

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	8,017	7,587	6,864	6,123	6,574	6,528	5,269	5,237	6,208	5,534	4,505	4,369
	106.10	134.20	111.40	109.00	154.90	80.60	57.50	68.20	63.20	156.40	37.70	54.00
	6,798	5,664	5,538	4,511	4,808	4,717	4,142	4,034	4,371	4,143	3,617	3,416
	1,251	1,347	1,216	1,327	1,219	1,164	1,026	1,066	1,116	1,210	1,063	1,037
	1,289	971.70	851.50	589.10	658.20	572.60	571.10	483.90	522.40	542.90	459.40	405.50
	1,368	1,239	1,140	1,034	1,005	971.40	946.50	879.20	883.50	837.00	817.30	752.90
	156.00	123.00	129.90	101.30	84.70	76.60	32.00	25.10	32.20	34.60	19.80	8.70
	554.70	508.40	359.60	301.90	238.10	237.90	229.00	233.60	215.30	205.30	194.80	184.20
	2,480	1,818	2,072	1,383	1,690	1,734	1,534	1,470	1,629	1,460	1,138	1,078
	1,325	2,057	1,438	1,722	1,921	1,892	1,184	1,271	1,900	1,547	925.50	1,007
	-18.20	-397.50	-84.90	-34.20	0.00	-219.60	0.00	0.00	0.00	0.00	0.00	0.00
	1,307	1,660	1,353	1,687	1,921	1,672	1,184	1,271	1,900	1,547	925.50	1,007
	354.20	318.40	388.30	454.00	434.00	423.20	179.50	373.10	436.10	321.20	213.80	226.40
	990.20	1,341	1,023	1,239	1,521	1,244	1,026	920.20	1,482	1,246	789.90	803.20
	9.35	12.65	10.36	12.51	14.58	11.64	10.18	9.05	14.11	11.66	7.59	7.92
Key metrics
	2,017	2,291	1,843	2,091	2,243	1,986	1,445	1,530	2,147	1,787	1,140	1,200
	25.20%	30.20%	26.80%	34.10%	34.10%	30.40%	27.40%	29.20%	34.60%	32.30%	25.30%	27.50%
	12.40%	17.70%	14.90%	20.20%	23.10%	19.10%	19.50%	17.60%	23.90%	22.50%	17.50%	18.40%
	—	4.90%	—	4.80%	—	6.20%	—	—	—	—	—	—
	22.00%	16.20%	30.30%	16.90%	5.90%	18.00%	17.00%	19.90%	—	—	—	—
	-34.90%	7.80%	-0.30%	34.60%	2.60%	-0.20%	29.90%	14.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	28,592	27,148	23,242	19,547	17,237	15,265	15,102	14,253	13,166	11,936	9,625
	460.70	509.50	269.50	284.10	186.60	224.70	37.20	113.90	201.10	113.20	128.60
	22,510	20,520	17,265	15,008	14,230	12,764	12,650	12,508	10,985	9,719	8,142
	5,142	5,110	4,373	4,580	4,123	4,043	3,888	3,460	2,674	2,555	1,831
	3,702	3,070	2,150	1,898	1,949	1,865	1,471	1,554	2,152	1,914	1,753
	4,781	4,418	3,681	3,138	2,766	2,434	2,490	2,414	2,124	1,854	—
	510.20	438.90	165.90	81.20	129.90	127.00	163.50	341.80	193.50	91.10	45.00
	1,725	1,408	915.80	764.10	722.70	713.00	724.80	696.50	598.60	—	375.00
	7,752	6,963	6,164	4,878	4,586	3,945	4,061	4,135	3,352	3,081	2,581
	6,542	7,138	6,246	4,823	3,194	2,725	2,490	1,859	2,382	2,331	1,612
	-534.80	-516.60	-219.60	-14.20	-604.20	112.70	-205.10	-363.60	0.00	0.00	-0.30
	6,007	6,621	6,027	4,809	2,590	2,838	2,285	1,495	2,382	2,331	1,612
	1,515	1,595	1,412	977.50	587.80	511.70	147.20	319.80	530.30	564.40	128.90
	4,593	5,124	4,673	3,973	2,092	4,618	2,185	1,204	1,899	1,810	1,517
	44.87	50.09	44.97	37.91	19.35	21.90	20.84	11.49	18.06	—	—
Key metrics
	8,242	8,468	7,108	5,654	3,442	3,678	3,173	2,534	3,174	2,422	2,032
	28.83%	31.20%	30.60%	28.90%	20.00%	24.10%	21.00%	17.80%	24.10%	20.30%	21.10%
	16.06%	18.90%	20.10%	20.30%	12.10%	30.30%	14.50%	8.50%	14.40%	15.20%	15.80%
	—	19.20%	22.00%	—	—	—	—	—	—	—	—
	—	16.80%	18.90%	13.40%	12.90%	1.10%	6.00%	8.30%	10.30%	24.00%	—
	—	9.60%	17.60%	89.90%	-54.70%	111.40%	81.40%	-36.60%	4.90%	19.40%	—
	—	-1,277	5,064	—	—	—	—	—	—	—	—
	—	0.41	1.45	—	—	—	—	—	—	—	—
	—	0.40	0.12	—	—	—	—	—	—	—	—
	—	10,914	2,343	—	—	—	—	—	—	—	—
	—	110.2	88.9	—	—	—	—	—	—	—	—
Balance sheet
	—	52,407	37,202	—	—	—	—	—	—	—	—
	—	19,906	17,046	—	—	—	—	—	—	—	—
	—	855.20	826.80	—	—	—	—	—	—	—	—
	—	5,416	4,025	—	—	—	—	—	—	—	—
	—	5,628	3,944	—	—	—	—	—	—	—	—
	—	1,449	679.40	—	—	—	—	—	—	—	—
	—	9,231	6,042	—	—	—	—	—	—	—	—
	—	2,845	2,306	—	—	—	—	—	—	—	—
	—	15,712	9,042	—	—	—	—	—	—	—	—
	—	11,770	3,170	—	—	—	—	—	—	—	—
	—	8,582	3,170	—	—	—	—	—	—	—	—
	—	3,188	0.00	—	—	—	—	—	—	—	—
	—	29,582	26,358	—	—	—	—	—	—	—	—
Cash flow
	—	2,117	6,777	—	—	—	—	—	—	—	—
	—	-8,296	-8,372	—	—	—	—	—	—	—	—
	—	5,997	2,031	—	—	—	—	—	—	—	—
	—	3,394	1,713	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,872	3,741	2,284	2,871	2,588	5,820	2,516	2,621	4,160	3,332	2,371	2,159
	123.70	495.10	473.80	541.50	157.10	185.40	77.50	326.70	106.60	361.10	106.80	534.50
	2,540	2,018	2,345	1,969	2,270	2,330	2,096	1,908	2,033	2,000	1,904	1,726
	861.50	936.70	849.50	890.80	853.70	720.80	635.80	704.80	725.70	737.20	681.60	705.90
	198.20	68.90	28.20	44.50	56.10	93.00	112.10	87.10	58.70	71.10	68.70	99.50
	561.40	513.90	496.40	468.70	487.20	476.30	425.00	436.50	424.40	405.10	373.00	377.70
	103.10	115.50	116.00	113.80	137.60	155.40	97.20	95.90	115.40	106.20	103.90	90.90
	151.90	150.90	144.30	136.00	130.00	128.00	131.60	133.70	130.60	130.60	127.70	124.90
	880.80	288.50	707.60	407.60	611.90	880.40	717.80	643.50	619.60	643.70	541.20	511.60
	455.70	2,218	412.50	1,444	474.90	3,675	497.20	1,039	2,234	1,694	574.30	968.10
	0.00	-106.80	-60.10	0.00	0.00	0.00	—	—	—	-8.60	—	—
	455.70	2,111	352.40	1,444	474.90	3,675	497.20	1,039	2,234	1,685	574.30	968.10
	116.10	389.00	55.90	287.00	90.20	861.00	26.60	249.50	532.70	279.70	123.90	163.10
	339.60	1,722	296.50	1,157	384.70	2,814	470.60	789.80	1,701	1,405	450.40	805.00
	3.38	17.11	2.95	11.49	3.82	27.96	4.68	7.85	16.90	13.89	4.45	7.96
Key metrics
	710.70	2,377	612.70	1,693	742.50	3,958	726.00	1,269	2,480	1,922	805.90	1,184
	24.70%	63.60%	26.80%	59.00%	28.70%	68.00%	28.90%	48.40%	59.60%	57.70%	34.00%	54.80%
	11.80%	46.00%	13.00%	40.30%	14.90%	48.30%	18.70%	30.10%	40.90%	42.20%	19.00%	37.30%
	—	7.90%	—	6.10%	—	15.70%	—	—	—	—	—	—
	11.00%	-35.70%	-9.20%	9.60%	-37.80%	74.60%	6.10%	21.40%	—	—	—	—
	-11.70%	-38.80%	-37.00%	46.40%	-77.40%	100.20%	4.50%	-1.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	11,768	11,484	15,116	10,819	8,732	7,982	7,790	6,347	6,493	5,823	3,274
	1,634	1,668	696.20	1,085	548.40	178.70	78.90	849.40	611.60	207.90	583.10
	8,872	8,603	8,368	7,655	7,044	6,677	5,993	5,587	5,176	4,533	3,215
	3,538	3,531	2,787	3,001	2,704	2,629	2,346	1,838	1,830	1,577	926.70
	339.80	197.70	350.90	283.20	362.70	288.10	153.30	97.90	390.60	318.60	228.80
	2,040	1,966	1,762	1,508	1,322	1,205	1,147	1,077	974.50	826.00	620.80
	448.40	482.90	463.90	390.70	278.20	134.90	70.90	233.90	88.40	63.90	11.10
	583.10	561.20	523.90	504.40	488.60	478.70	451.10	428.90	349.80	293.10	250.90
	2,284	2,016	2,601	2,174	—	1,989	1,973	1,895	1,615	1,642	1,280
	4,530	4,549	7,445	4,248	2,236	1,483	1,876	1,610	1,928	1,497	642.20
	-166.90	-166.90	0.00	-8.60	-203.80	-319.30	-187.50	-52.00	—	—	—
	4,363	4,382	7,445	4,240	2,032	1,164	1,688	1,558	1,928	1,497	642.20
	848.00	822.10	1,670	798.30	503.00	306.00	212.30	204.10	326.40	406.40	19.70
	3,515	3,560	5,775	3,442	1,529	857.90	1,476	1,413	1,602	1,091	661.90
	34.93	35.38	57.39	34.01	15.06	8.38	14.42	13.22	15.65	—	—
Key metrics
	5,394	5,426	8,432	5,135	2,799	1,778	2,210	2,220	2,367	1,854	904.20
	45.84%	47.20%	55.80%	47.50%	32.10%	22.30%	28.40%	35.00%	36.50%	31.80%	27.60%
	29.87%	31.00%	38.20%	31.80%	17.50%	10.70%	18.90%	22.30%	24.70%	18.70%	20.20%
	—	17.20%	32.30%	—	—	—	—	—	—	—	—
	—	-24.00%	39.70%	23.90%	9.40%	2.50%	22.70%	-2.20%	11.50%	77.80%	—
	—	-38.40%	67.80%	125.10%	78.20%	-41.90%	4.50%	-11.80%	46.90%	64.80%	—
	—	1,335	2,209	—	—	—	—	—	—	—	—
	—	0.63	0.54	—	—	—	—	—	—	—	—
	—	0.31	0.39	—	—	—	—	—	—	—	—
	—	7,104	8,236	—	—	—	—	—	—	—	—
	—	292.4	214.5	—	—	—	—	—	—	—	—
Balance sheet
	—	33,880	32,317	—	—	—	—	—	—	—	—
	—	16,252	15,315	—	—	—	—	—	—	—	—
	—	327.00	103.00	—	—	—	—	—	—	—	—
	—	8,495	8,162	—	—	—	—	—	—	—	—
	—	2,178	1,952	—	—	—	—	—	—	—	—
	—	545.90	280.40	—	—	—	—	—	—	—	—
	—	5,011	4,136	—	—	—	—	—	—	—	—
	—	1,472	1,232	—	—	—	—	—	—	—	—
	—	5,593	7,851	—	—	—	—	—	—	—	—
	—	7,431	8,339	—	—	—	—	—	—	—	—
	—	3,198	5,477	—	—	—	—	—	—	—	—
	—	4,233	2,862	—	—	—	—	—	—	—	—
	—	23,672	21,190	—	—	—	—	—	—	—	—
Cash flow
	—	2,234	3,114	—	—	—	—	—	—	—	—
	—	569.60	-4,504	—	—	—	—	—	—	—	—
	—	-2,580	1,384	—	—	—	—	—	—	—	—
	—	899.00	904.90	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +9.56%
Sales CAGR 5Y: +8.07%
Sales CAGR 10Y: —
Profit CAGR 3Y: +32.53%
Profit CAGR 5Y: +19.25%
Profit CAGR 10Y: —
Sales YoY (TTM): -13.12%
Profit YoY (TTM): -21.17%

Consolidated

Sales CAGR 3Y: +16.35%
Sales CAGR 5Y: +12.45%
Sales CAGR 10Y: —
Profit CAGR 3Y: +34.80%
Profit CAGR 5Y: +18.58%
Profit CAGR 10Y: —
Sales YoY (TTM): +21.11%
Profit YoY (TTM): -2.51%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 74.99%

Holder	Type	Holding	Previous	Change
Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees)	Promoter	74.98%	—	—
Life Insurance Corporation Of India	Public	5.41%	—	—
Parag Parikh Flexi Cap Fund	Public	2.02%	—	—
Kotak Flexicap Fund	Public	1.19%	—	—
Arati Rajiv Mehta	Promoter Group	0.01%	—	—
VINS Hospital Private Limited	Promoter Group	0.00%	—	—
Pankaj Ramanbhai Patel	Promoter	0.00%	—	—
Yelena Hospitals LLP	Promoter Group	0.00%	—	—
Shivani Pankajbhai Patel	Promoter Group	0.00%	—	—
Zydus Hospitals and Healthcare Research Private Limited	Promoter Group	0.00%	—	—
Zandra Infrastructure LLP	Promoter Group	0.00%	—	—
Samar Babubhai Patel	Promoter Group	0.00%	—	—
Ayushi Rajiv Mehta jointly with Arati Rajiv Mehta	Promoter Group	0.00%	—	—
Zydus Hospital LLP	Promoter Group	0.00%	—	—
Vertius LLP	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Credit Rating11 Sep 2026 · Company Update / Credit Rating
The Company is going to participate in J.P. Morgan India Conference, 2026, on September 21, 2026.11 Sep 2026 · Company Update / Analyst / Investor Meet
Newspaper publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on September 9, 2026.9 Sep 2026 · Company Update / Newspaper Publication
Settlement Agreement5 Sep 2026 · Company Update / General
Transcript of the 31st Annual General Meeting1 Sep 2026 · AGM/EGM / AGM
Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH.31 Aug 2026 · Company Update / Press Release / Media Release
Incorporation of a wholly owned subsidiary in Gift City, Gandhinagar, Gujarat26 Aug 2026 · Company Update / General
ESG Rating25 Aug 2026 · Company Update / General
Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 201524 Aug 2026 · Company Update / General
Investor Presentation23 Aug 2026 · Company Update / Investor Presentation
ESG Rating21 Aug 2026 · Company Update / General
Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.21 Aug 2026 · Company Update / Press Release / Media Release
Transcript of the post results earnings call held on August 11, 202618 Aug 2026 · Company Update / Earnings Call Transcript
The management of the Company will meet the investors in Singapore and Hong Kong between August 24, 2026, to August 26, 2026, in the form of a Non-Deal Roadshow (NDR).17 Aug 2026 · Company Update / Analyst / Investor Meet
Update on Investor Conference12 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper cutting with regard to publication of unaudited financial results for the quarter ended on June 30, 2026, in Financial Express on August 12, 2026.12 Aug 2026 · Company Update / Newspaper Publication
Regulation 44(3) disclosure of AGM 202611 Aug 2026 · AGM/EGM / AGM
Change in Directors11 Aug 2026 · Company Update / Change in Directorate
Scrutinizer''s report11 Aug 2026 · AGM/EGM / AGM
Outcome of AGM11 Aug 2026 · AGM/EGM / AGM
Audio Link of the Investor Call held on August 11 202611 Aug 2026 · Company Update / Analyst / Investor Meet
Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 201511 Aug 2026 · Company Update / General
Press Release11 Aug 2026 · Company Update / Press Release / Media Release
Press Release11 Aug 2026 · Company Update / Press Release / Media Release
Investor Presentation11 Aug 2026 · Company Update / Investor Presentation
Unaudited financial results for the quarter ended on June 30, 202611 Aug 2026 · Board Meeting / Outcome of Board Meeting
Unaudited financial results for the quarter ended on June 30, 202611 Aug 2026 · Result / Financial Results
Zydus launches REVAHALE, India''s first once-daily nebulised LAMA for COPD.10 Aug 2026 · Company Update / Press Release / Media Release
The Company is going to participate in Motilal Oswal 22nd Annual Global Investor Conference, 2026 on August 18, 2026.10 Aug 2026 · Company Update / Analyst / Investor Meet
Zydus announces Final Approval from the USFDA for Indocyanine Green for Injection with 180-Days CGT exclusivity.4 Aug 2026 · Company Update / Press Release / Media Release
Newspaper publication of notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on August 4, 2026.4 Aug 2026 · Company Update / Newspaper Publication
Investor Conference4 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Conference4 Aug 2026 · Company Update / Analyst / Investor Meet
EIR from the USFDA1 Aug 2026 · Company Update / Press Release / Media Release
Q1 FY27 post results earning call details30 Jul 2026 · Company Update / Analyst / Investor Meet
Receipt of order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat.29 Jul 2026 · Company Update / General
Disruption of operations due to heavy rain and water logging25 Jul 2026 · Company Update / Strikes /Lockouts / Disturbances
Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR.23 Jul 2026 · Company Update / Press Release / Media Release
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve unaudited financial results ....20 Jul 2026 · Board Meeting / Board Meeting
Reply to the clarification sought from the company15 Jul 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.0000	24 Jul 2026	24 Jul 2026	—
Buy Back of Shares	29 May 2026	29 May 2026	—
Final Dividend - Rs. - 11.0000	25 Jul 2025	25 Jul 2025	—
Final Dividend - Rs. - 3.0000	26 Jul 2024	26 Jul 2024	—

Board meetings

11 Aug 2026 Board Meeting - Financial Results